Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
Articles > Article · 2023
Authors: Erhan GÖKMEN, Laurence Albiges, Howard Gurney, Vagif Atduev, Christina Suarez, Miguel A Climent, David Pook, Piotr Tomczak, Philippe Barthelemy, Jae Lyun Lee, Viktor Stus, Thomas Ferguson, Pawel Wiecheno, Louis Lacombe, Craig Gedye, Rodolfo Perini, Manish Sharma, Xiang Peng, Chung-Han Lee
The Lancet Oncology, Journal Indexed in SSCI, International, WoS, 2023, vol 24, pp 881-891